Scienture Holdings, Inc. SCNX
3.04 USD -0.11 (-3.49%)
At closeNov 11, 2026, 4:00 AM EST
3.01 -0.03 -0.99%
Pre-market · Nov 11, 4:00 AM ET
3.04 Day range 3.15
2.64 52-week range 19.48
- YTD
- -76.16%
- 1 year
- -83.59%
News
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 16.1% to $0.92 during Thursday's after-market session. The company's market cap stands at $2.2 million. CareDx (NASDAQ:CDNA) stock rose 15.0% to…
benzinga.com Maxim Group Maintains Buy on Scienture Holdings, Adjusts Price Target To $6 (reverse stock split 1:25) Maxim Group analyst Naz Rahman maintains Scienture Holdings (NASDAQ:SCNX) with a Buy, adjusts target to $6 from $37.5 (reverse stock split 1:25).
benzinga.com Scienture Holdings Reports Preliminary Q3 Revenue Growth To $1.22M; Co Targeting Profitability In 2027 Preliminary Unaudited Third Quarter Revenue Increased 256% Sequentially to Approximately $1.22 Million, Supported by Continued Arbli™ Growth and the Commercial Launch of REZENOPY™Two FDA-Approved…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 17.9% to $0.16 during Monday's after-market session. The market value of their outstanding shares is at $2.8 million. SCWorx (NASDAQ:WORX)…
benzinga.com SCIENTURE HOLDINGS Reports Preliminary Q3 Revenue Of ~$1.22M SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) ("Scienture"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and…
benzinga.com EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability Scienture Holdings reports Q3 revenue of $1.22M, up 256% QoQ, driven by Arbli growth and the launch of Rezenopy.